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The mood-improving actions of antidepressants do not
depend on neurogenesis but are associated with neuronal
remodeling
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The mechanisms underlying the initiation/onset of, and the recovery from, depression are still
largely unknown; views that neurogenesis in the hippocampus may be important for the
pathogenesis and amelioration of depressive symptoms have gained currency over the years
although the original evidence has been challenged. In this study, an unpredictable chronic
mild stress protocol was used to induce a depressive-like phenotype in rats. In the last 2 weeks
of stress exposure, animals were treated with the antidepressants fluoxetine, imipramine, CP
156,526 or SSR 1494515, alone or combined with methylazoxymethanol, a cytostatic agent
used to arrest neurogenesis. We found that antidepressants retain their therapeutic efficacy in
reducing both measured indices of depression-like behavior (learned helplessness and
anhedonia), even when neurogenesis is blocked. Instead, our experiments suggest re-
establishment of neuronal plasticity (dendritic remodeling and synaptic contacts) in the
hippocampus and prefrontal cortex, rather than neurogenesis, as the basis for the restoration
of behavioral homeostasis by antidepressants.
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Introduction
Neuronal plasticity and neurogenesis in the hippo-
campus are two, not necessarily mutually exclusive,
mechanisms proposed to underlie the behavioral
improvement seen in response to antidepressant
treatments.1–3 Neurogenesis occurs in many mam-
mals,4,5 including humans;6 even thought this process
is generally viewed as a crucial promoter of neuronal
plasticity, some studies have recently disputed the
relevance of neurogenesis for certain behavioral
adaptations.7 Studies showing that hippocampal
neurogenesis is reduced in animal models of depres-
sion, and stimulated by a range of antidepressants,8–11
led to the proposal that neurogenesis may have a role
in the pathogenesis of depression. The importance of
altered neurogenesis in the precipitation of depres-
sion-like behavior has, however, been challenged
recently.12,13 Questions have also been raised14–16
regarding an earlier proposal by Santarelli et al.,17
that hippocampal neurogenesis is essential for the
manifestation of behavioral improvement after the
administration of antidepressants. In contrast, stress,
an important trigger of depression, is known to reduce
neurogenesis18 and impair synaptic plasticity and
dendritic arborization in the hippocampus19 as well
as in ‘executive centers’ such as the prefrontal cortex
(PFC).20–22 Antidepressants attenuate hippocampal
volume loss in depressed patients23 and can reverse
some of the deleterious effects of stress on synaptic/
dendritic structure.24
In this study, we therefore analyzed the neuro-
trophic hypothesis of depression in its wider context,
focusing on hippocampal neurogenesis and neuronal
plasticity in the hippocampus and PFC. An unpre-
dictable chronic mild stress (CMS) paradigm was
used for 6 weeks to induce core symptoms of
depressive-like behavior in rats.25 Anhedonia, learned
helplessness and anxiety-like behaviors were as-
sessed using standardized assays (sucrose preference
test, forced swimming test (FST) and novelty sup-
pressed feeding (NSF) test, respectively) at the end of
the experimental period. During the last 2 weeks of
CMS, standard antidepressants of two different
classes (imipramine and fluoxetine) and two putative
antidepressants (CP 156,526, a type 1 corticotropin-
releasing hormone receptor antagonist, and SSR
1494515, a type 1b arginine vasopressin receptor
antagonist) were administered daily. To evaluate the
requirement of hippocampal neurogenesis for the
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behavioral effects of antidepressants, the cytostatic
agent methylazoxymethanol (MAM) was co-adminis-
tered with these drugs in different subgroups of
animals. All animals received a single injection of
bromodeoxyuridine (BrdU) 1 day before killing and
samples of the hippocampus and PFC were pre-
pared for immunocytochemical analysis of prolifer-
ation (BrdU and Ki-67) and differentiation markers
(doublecortin (DCX), neuronal nuclei (NeuN), glial
fibrillary acidic protein (GFAP)), stereological estima-
tions of total number of neurons and volumes, Golgi
impregnation to assess dendritic arborization and
spine shape and number by three-dimensional
morphometry, and measurement of mRNA levels of
the synaptic remodeling/plasticity proteins neural




Male Wistar rats (Charles-River Laboratories, Barcelona,
Spain), weighing 300–400 g and aged 3 months were
used in this study. Animals were housed (three per
cage) under standard laboratory conditions (12 h light/
12 h dark cycle, at 22 1C, relative humidity of 55%; free
access to food and water). Animals were assigned to one
of two main treatment groups (control and CMS—see
below). All procedures were carried out in accordance
with European Union Directive 86/609/EEC and NIH
guidelines on animal care and experimentation.
Drugs
The drugs used were fluoxetine (10 mg kg1; Kemprotec,
Middlesborough, UK), imipramine (10 mg kg1;
Sigma-Aldrich, St Louis, MO, USA), CP 156,526
(20 mg kg1; Pfizer, New York, NY, USA) and SSR
149415 (30 mg kg1; Sanofi-Synthelabo, Montpellier,
France) and MAM (7 mg kg1; National Cancer
Institute, Midwest Research Institute, Kansas City,
MO, USA). Fluoxetine, imipramine, CP 156,526 and
SSR 149415 were administered intraperitoneally (i.p.;
1 ml kg1); MAM was administered subcutaneously
(0.45 ml kg1). Compounds were dissolved in 5%
DMSO in 0.9% saline. All animals received an
injection of BrdU (100 mg kg1 i.p.) 24 h before killing.
As MAM is a powerful cytostatic drug, we were
concerned about the potential confounding effects of
blocking mitosis in organs other than the brain, such
as the epithelium of the intestine.26 Pilot studies
showed that MAM at a dose of 7 mg kg1 per day
reduces neurogenesis (BrdU and Ki-67 immunostain-
ing) by approximately 60% in the dentate gyrus of all
(including CMS) experimental groups. As an index of
general health,27,28 we assessed locomotor activity
(ambulation in an open field, swimming speed in a
water maze) and fur quality; MAM-treated and
control rats scored equally on these end points.
Chronic mild stress
A slightly modified version of a CMS protocol25 was
used. It consisted of chronic exposure to unpredict-
able mild stressors (confinement to a restricted space
for 1 h, placement in a tilted cage (301) for 3 h, housing
on damp bedding for 8 h, overnight illumination, 18 h
food deprivation followed by exposure to inaccessible
food for 1 h, water deprivation for 18 h followed by
exposure to an empty bottle for 1 h, and reversed
light/dark cycle for 48 h every 7 days) over 6 weeks.
During the last 2 weeks of CMS, animals were given
daily injections of either saline (CMSþ saline),
salineþMAM, or one of the four antidepressants
with or without MAM; each of these subgroups
consisted of 24 animals; in addition, saline- or
MAM-treated control animals that were not exposed
to CMS were also used (n= 48).
Sucrose preference test
Anhedonia was assessed weekly during exposure to
CMS using the sucrose preference test. Briefly,
animals were allowed to habituate to the sucrose
solution 1 week before the CMS protocol to establish
baseline preference levels. To test sucrose preference,
animals that were food- and water-deprived for 18 h
were presented with two preweighed bottles contain-
ing 1% sucrose solution or tap water for a period of
1 h. Sucrose preference was calculated according to
the formula: sucrose preference = (sucrose intake/
(sucrose intakeþwater intake))100, as previously
described.29 Anhedonia was defined as a reduction in
sucrose preference relative to baseline levels.
Forced swimming test
Learned helplessness was evaluated in the FST on the
last day of exposure to CMS. Twenty-four hours after a
pretest session (10 min), the FST was conducted by
placing rats in cylinders filled with water (25 1C;
depth 30 cm) for a period of 5 min. Test sessions were
assessed using a camera connected to a video tracking
system (Viewpoint); the system automatically calcu-
lated immobility time and latency to immobility.
Learned helplessness behavior was defined as an
increase in time of immobility and a decrease in
latency to immobility.
Novelty suppressed feeding
To characterize anxiety-like behavior, NSF was
assessed on the last day of the CMS paradigm. This
test was conducted in an independent group of
animals prepared as before (controls±MAM;
CMS±MAM; CMS±fluoxetine or imipramine or CP
156,526 or SSR 149415; CMS±fluoxetine or imipra-
mine or CP 156,526 or SSR 149415±MAM; n= 12 per
group). Based on previous studies,30 animals were
deprived of food for 23 h before being placed in a
novel environment for 10 min (an open-field arena;
MedAssociates Inc.); a single food pellet was placed
in the center of the arena. Upon reaching the pellet,
animals were returned to their home cages and
presented with preweighed food over a period of
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5 min. Latency to feeding in the open field was used
as an index of anxiety-like behavior; the amount of
food consumed in the home cage provided a measure
of appetitive drive.
Immunostaining procedures
Animals were rapidly decapitated and brains fixed in
4% paraformaldehyde. Serial coronal sections, ex-
tending over the entire length of the telencephalon,
were cut and stained for BrdU (1:50; Dako, Glostrup,
Denmark) or Ki-67 (1:200; Novocastra, Newcastle-
upon-Tyne, UK). BrdU is incorporated into DNA only
during the S-phase of the mitotic process; Ki-67 is a
nuclear protein expressed in all phases of the cell
cycle except for the resting phase.31 Sections were
then double stained for DCX (for neuroblasts; 1:500;
Abcam, Cambridge, UK), NeuN (for neurons; 1:100;
Chemicon, Temecula, CA, USA) or GFAP (for glia;
1:200; Dako). A universal detection system (BioGen-
ex, San Ramon, CA, USA) and diaminobenzidine
(0.025% and 0.5% H2O2 in Tris–HCl 0.05 M, pH 7.2)
were used to visualize immunostained cells after
counterstaining with hematoxylin. Proliferation den-
sities were estimated in the subgranular zone (SGZ;
defined as a two-cell layer-thick zone on the inner
side of the granule cell layer of the dentate gyrus),
using an Olympus BX51 optical microscope and
Newcast software (Visiopharm). The density of BrdU,
Ki-67 labeled cells in the SGZ was estimated in every
eighth section, as a ratio between the total number of
immunostained cells and the volume of the SGZ. For
each animal, 50–100 BrdU and/or Ki-67-positive cells
within the SGZ of the dentate gyrus were analyzed
after double staining with neuronal (DCX or NeuN) or
glial (GFAP) markers, using a confocal microscope
(Olympus FV1000).
Structural analysis
Total number of neurons in the hippocampal forma-
tion and in the medial PFC (mPFC) were estimated
using the optical fractionator (see Cerqueira et al.22 for
details) in the right hemisphere of six animals from
each experimental group. Brains were postfixed in
4% paraformaldehyde for 48 h and embedded in
glycolmethacrylate. Volumes were determined by
the Cavalieri’s principle using the StereoInvestigator
software (Microbrightfield). For the three-dimen-
sional morphometric analysis, six animals from each
treatment group were transcardially perfused with
0.9% saline and processed.32 Briefly, brains were
immersed in Golgi-Cox solution33 for 21 days;
transferred to a 30% sucrose solution and cut on a
vibratome. Coronal sections (200mm thick) were
collected in 6% sucrose and blotted dry onto
gelatin-coated microscope slides. They were subse-
quently alkalinized in 18.7% ammonia, developed in
Dektol (Kodak, Rochester, NY, USA), fixed in Kodak
Rapid Fix, dehydrated and xylene cleared before
coverslipping. Dendritic arborization and spine num-
bers and shape were analyzed in the dentate gyrus,
CA3 region of the hippocampus and layer II/III of the
prelimbic area of the mPFC. For each selected neuron,
all branches of the dendritic tree were reconstructed
at  600 (oil) magnification using a motorized micro-
scope (Axioplan 2; Carl Zeiss) and Neurolucida
software (Microbrightfield). A three-dimensional ana-
lysis of the reconstructed neurons was performed
using NeuroExplorer software (Microbrightfield). For
each animal, 40 neurons were studied and measure-
ments from individual neurons from each animal
were averaged. Several aspects of dendritic morphol-
ogy were examined. Total dendritic length and the
number of primary dendrites and dendritic branching
points were compared across experimental groups.
Dendritic spine density (number of spines/dendritic
length) was determined in branches that were either
parallel or at acute angles to the coronal surface of the
section. In dentate granule cells, proximal and distal
branches were analyzed for each neuron; basal
branches and proximal and distal apical branches in
pyramidal neurons in the CA3 region and prelimbic
area of the mPFC were analyzed. Three-dimensional
Sholl analysis was used to evaluate the arrangement
of the dendritic material; for this, the number of
dendritic intersections with concentric spheres posi-
tioned at radial intervals of 20mm was determined. To
assess changes in spine morphology, spines in the
selected segments were classified into mushroom-
shaped, thin, wide and ramified spines34 and the
proportion of spines in each category was calculated
for each neuron.
qPCR measurements
Levels of Ncam1 and Syn1 mRNA expression were
determined by quantitative PCR (qPCR) in hippocam-
pi and PFC derived from four animals of each
treatment group. Total RNA (2 mg) were reverse
transcribed using oligo-dT primers of the Superscript
First-strand Synthesis system for reverse transcrip-
tion–PCR (Invitrogen, Carlsbad, CA, USA). Hypo-
xanthine guanine phosphoribosyl transferase (Hprt)
was used as internal standard for normalization.
Oligonucleotide primers for Ncam1 (sense AAAGGA
TGGGGAACCCATAG, antisense TAGGTGATTTTG
GGCTTTGC), Syn1 (sense CACCGACTGGGCAAAAT
ACT, antisense TCCGAACTTCCATGTCC) and
Hprt (sense GCAGACTTTGCTTTCCTTGG, antisense
TCCACTTTCGCTGATGACAC) were designed using
the Primer3 software on the basis of the GenBank
sequences NM_031521, NM_019133 and NM_012583,
respectively. Real-time PCR reactions were performed
on a LightCycler (Roche Diagnostics, Basel, Switzer-
land), using QuantiTect SYBR Green RT-PCR (Qiagen,
Hilden, Germany).
Statistical analysis
After confirmation of homogeneity, appropriate sta-
tistical tests were applied to the data. Repeated
measures ANOVA were used to analyze sucrose
preference test results, body mass and physical state
of the fur. Two-factor ANOVA was used to evaluate
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other behavioral data as well as cell densities and
immunostaining results. Differences between groups
were then determined by Tukey’s honestly significant
difference test (Tukey HSD) post hoc analysis.
Statistical significance was accepted for P< 0.05.
Results are expressed as mean±s.e.m.
Results
Behavioral results
Anhedonia was assessed weekly in the sucrose
consumption test. Sucrose preference was reduced
in CMS animals (F4,176 = 279.25, P< 0.001). This
anhedonic phenotype was reversed by imipramine,
CP 156,526 and SSR 149415 after the first, and by
fluoxetine after the second week of treatment
(P< 0.001 in all cases; Figure 1a). Repeated measures
ANOVA failed to reveal an interaction between
antidepressant treatment and co-administration of
MAM (F8, 220 = 0.95, P= 0.469). The FST revealed a
significant increase in immobility time in stressed
animals (F1, 44 = 18.56, P< 0.001). Chronic administra-
tion of fluoxetine (P= 0.006), imipramine (P< 0.001),
CP 156,526 (P< 0.001) and SSR 149415 (P< 0.001)
reversed this sign of depressive-like behavior even
when MAM was administered (Figure 1b). Exposure
to CMS significantly increased the latency to feed in
the NSF paradigm (F1, 44 = 5.02, P= 0.03), an effect that
was reversed by fluoxetine, imipramine and CP
156,526 (P< 0.001 in all cases), confirming the
anxiolytic properties of these drugs (Figure 1c). The
co-administration of MAM increased this measure in
all experimental groups (P< 0.001).
Cell proliferation and differentiation
The density of cells labeled for the endogenous
marker of proliferation, Ki-67, was significantly
reduced in animals exposed to CMS (F1, 20 = 29.77,
P< 0.001; Figure 1d). Treatment with either fluoxe-
tine, imipramine, CP 156,526 or SSR 149415 restored
this parameter to control levels (P< 0.001 in all cases).
The density of Ki-67-positive cells was significantly
reduced in animals receiving concomitant injections
of MAM (P< 0.001). The percentage of Ki-67-immu-
nopositive cells that colabeled with antibodies
against DCX (a marker of early neuroblasts) in the
SGZ of the dentate gyrus was significantly lower in
CMS-treated rats (F1, 20 = 13.72, P= 0.001) but reversed
by fluoxetine (P= 0.001), imipramine (P= 0.008), CP
156,526 (P= 0.001) and SSR 149415 (P= 0.005; Figure
1e). The percentage of cells showing colocalization of
Ki-67 and DCX was reduced in all groups receiving
MAM (P< 0.001).
The density of BrdU-positive cells in the SGZ
was significantly decreased in animals exposed to
CMS (F1, 20 = 29.6, P< 0.001), an effect reversed after
chronic administration of fluoxetine, imipramine, CP
156,526 or SSR 149415 (P< 0.001 in all cases;
Supplementary Figure S1a). Administration of MAM
significantly reduced the density of BrdU positive
Figure 1 Amelioration of behavioral symptoms of depression by antidepressant drugs does not depend on neurogenesis. (a)
Anhedonia was assessed weekly in the sucrose consumption test (n= 12 per group; *P< 0.001). (b) Learned helplessness was
evaluated in the forced swimming test (FST) at the end of the chronic mild stress (CMS) protocol (n= 12 per group;
**P< 0.001; # P< 0.006). (c) Anxiety-like behavior in the novelty suppressed feeding paradigm at the end of the CMS protocol
(n= 12 per group; *P< 0.001; **Pp0.001; # P= 0.03). (d) The density of recently-mitotic cells labeled for the endogenous
marker of proliferation Ki-67 in the subgranular zone (SGZ) of the dentate gyrus (n= 6 per group; *P< 0.001; **P< 0.001;
#Pp0.001). (e) Percentage of Ki-67-immunopositive cells that co-labeled with antibodies against doublecortin (DCX, a marker
of early neuroblasts) in the SGZ (n= 6 per group; *P< 0.001; **P= 0.001; #P< 0,008). (f) Image of a niche of newly formed
neurons in the SGZ, obtained by confocal microscopy. Red: Ki-67-positive cells; green: DCX-positive cells. Confocal stacks
(image shown in f) resliced in the x-z plane (g) and in the y-z plan (h). Data represented as mean±s.e.m. Asterisk represents
the effect of methylazoxymethanol (MAM) in every experimental group. Double asterisk represents the comparison between
control and CMS groups. Cardinal represents the effect of antidepressant treatment.
Restoration of behavioral homeostasis by antidepressants
JM Bessa et al
767
Molecular Psychiatry
cells in control and antidepressant-treated animals
(P< 0.001), thus confirming antiproliferative effect of
this cytostatic drug. The percentage of BrdU-positive
cells that double-labeled with anti-NeuN in the SGZ
was decreased by exposure to CMS (F1, 20 = 8.51,
P= 0.008; Supplementary Figure S1b). The chronic
administration of fluoxetine (P= 0.006), imipramine
(P= 0.01), CP 156,526 (P= 0.001) and SSR 149415
(P= 0.005) reversed this change. Administration of
MAM significantly reduced the percentage of BrdU-
and NeuN-positive cells in all experimental groups
(P< 0.001). The percentage of BrdU-positive cells
labeled with GFAP in the SGZ was not significantly
altered after exposure to CMS, or after administration
of antidepressant drugs or MAM, alone or in
combination (Supplementary Figure S1c).
Structural analysis
As shown in Figure 2a, CMS induced a volumetric
reduction in the molecular layer of the dentate gyrus
(26%) and strata radiatum of CA3 (32%), CA1 (22%)
and subiculum (Sub; 28%); these atrophic changes
were reversed by all antidepressants (for all regions
P< 0.05). CMS also induced volumetric reductions in
the mPFC (Figure 2b), specifically in the superficial
layers of the cingulum (Cg), prelimbic (PL) and
infralimbic (IL) regions, as well as in deep layers of
the PL and IL. Again, all antidepressants tested
efficiently promoted volumetric recovery in all these
layers (for all regions P< 0.05) to a similar extent.
None of the experimental groups showed significant
neuronal loss in either the hippocampus or mPFC
(data not shown).
The three-dimensional morphometric analysis of
Golgi-impregnated neurons revealed that CMS
induces significant atrophy of granule cell dendrites
(F1, 20 = 32.06, P< 0.001) and CA3 pyramidal neurons
(F1, 20 = 46.35, P< 0.001; Figure 3d and e), as measured
by total dendritic lengths. Administration of either
fluoxetine, imipramine, CP 156,526 or SSR 149415
reversed this effect in both regions (P< 0.005 in
all cases). Significant dendritic atrophy was also
observed in pyramidal neurons in the PFC after
exposure of animals to CMS (F1, 20 = 130.09,
P< 0.001; Figure 3f); these changes were attenuated
by concomitant treatment with imipramine, CP
156,526 and SSR 149415 (P< 0.001 in all cases) but
not by fluoxetine. The dendritic atrophy observed in
CA3 and PFC pyramidal neurons, and its reversal by
antidepressant treatment, was confined to apical
dendrites; basal dendritic lengths were not signifi-
cantly altered by any of the treatments (Supplemen-
tary Figure S2). None of the treatments resulted in
changes in the density of spines in dendrites of the
dentate granule neurons (Figure 3g). In contrast, CMS
was associated with significant loss of spines in the
proximal, but not distal, dendrites of CA3 pyramidal
neurons (F1, 20 = 25.83, P< 0.001; Figure 3h); this effect
was attenuated by fluoxetine (P= 0.001), imipramine
(P< 0.001), CP 156,526 (P= 0.011) and SSR 149415
(P< 0.001) treatment. Decreased spine densities
in the proximal (F1, 20 = 84.86, P< 0.001) and distal
(F1, 20 = 134.89, P< 0.001) dendrites of PFC pyramidal
neurons were observed in CMS-treated rats (Figure 3i).
All antidepressant drugs tested reversed these
changes (P< 0.001, for proximal and distal dendrites
in all cases). The CMS protocol did not cause spine
density changes in the basal dendrites of hippocam-
pal or PFC pyramidal neurons (data not shown). The
number of dendritic branch points was significantly
reduced in the dentate gyrus (F1, 20 = 11.503, P< 0.001)
and PFC (F1, 20 = 45.629, P< 0.001) of animals exposed
to CMS (Supplementary Figure S3a and c). In the
dentate gyrus, this effect was reversed by fluoxetine
(P< 0.001), imipramine (P< 0.001), CP 156,526
(P= 0.002) and SSR 149415 (P< 0.001); treatment with
fluoxetine (P= 0.015), imipramine (P< 0.001), CP
156,526 (P< 0.001) and SSR 149415 (P< 0.001) atten-
uated the effects of stress in the PFC. Despite the lack
of effect of CMS in the CA3 region (Supplementary
Figure S3b), there was a significant increase in the
number of dendritic branch points in stressed animal
treated with CP 156,526 (P= 0.022). The number of
primary dendrites was not influenced by either stress
exposure or treatment with antidepressants in any of
the regions analyzed (Supplementary Figure S3d, e
and f). Treatment with the antiproliferative agent
MAM did not influence total dendritic length, spine
Figure 2 Schematic representation of structural changes in
the hippocampus (a) and medial prefrontal cortex (b).
Chronic mild stress (CMS) induced a volumetric reduction
in the molecular layer of the dentate gyrus and strata
radiatum of CA3, CA1 and subiculum; these atrophic
changes were reversed by all antidepressants (n= 6 per
group; for all regions P< 0.05). Exposure to stress induced
volumetric reductions in the medial prefrontal cortex
(mPFC), specifically in the superficial layers of the
cingulum (Cg), prelimbic (PL) and infralimbic (IL) regions,
as well as in deep layers of the PL and IL. All antidepres-
sants efficiently promoted volumetric recovery in all these
layers (n= 6 per group; for all regions P< 0.05) to a similar
extent (indicated changes in percentage refer to those found
in CMSþ fluoxetine-treated animals). None of the experi-
mental groups showed significant neuronal loss in either
the hippocampus or mPFC (data not shown).
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densities, number of dendritic branch points and
primary dendrites (hippocampus and PFC) in any of
the experimental groups. Sholl analysis of dendritic
distribution revealed significantly fewer dendritic
intersections in the dentate gyrus (F1, 20 = 5.717,
P= 0.027) and PFC (F1, 20 = 53.891, P< 0.001) of
stressed animals (Supplementary Figure S3g and i).
In the dentate gyrus, the CMS effect was reversed by
fluoxetine (P= 0.003), imipramine (P< 0.001), CP
156,526 (P< 0.001) and SSR 149415 (P< 0.001);
similarly, fluoxetine (P= 0.001), imipramine
(P< 0.001), CP 156,526 (P< 0.001) and SSR 149415
(P< 0.001) attenuated the effects of stress in the PFC.
Although CMS did not induce any significant
changes in the CA3 region (Supplementary Figure
S3h), treatment with fluoxetine (P= 0.029) and imi-
pramine (P= 0.0028) led to an increase in dendritic
intersections. None of the experimental groups that
additionally received the antiproliferative agent
MAM showed changes in dendritic distribution in
any of the areas evaluated (data not shown).
The morphological classification of dendritic
spines revealed that the percentage of mushroom-
type spines in the proximal dendrites of dentate
granule neurons was significantly decreased in rats
exposed to CMS (F1, 20 = 8.06, P= 0.01); in contrast,
CMS-treated animals displayed an increase in the
percentage of thin-type spines (F1, 20 = 258.35,
P< 0.001; Supplementary Figure S4a). These changes
were reversible after treatment with all of the
antidepressants tested (P< 0.001 in all cases). The
percentage of mushroom-type spines in the distal
dendrites of dentate granule neurons was also
significantly decreased in CMS-exposed animals
(F1, 20 = 44.68, P< 0,001); both CP 156,526 (P= 0.004)
and SSR 149415 (P= 0,002), but not fluoxetine or
imipramine, reversed this effect (Supplementary
Figure S4b). The percentage of thin-type spines was
increased in CMS-treated rats (F1, 20 = 273.52,
P< 0.001) and restored to control levels by all
antidepressants (P< 0.001 in all cases). No changes
were observed on the morphology of dendritic spines
in CA3 pyramidal neurons (Supplementary Figure
S4c and d). A significant increase in the percentage
of thin-type spines in the proximal dendrites of
pyramidal neurons of the mPFC was observed in
animals exposed to CMS (F1, 20 = 35.43, P< 0.001)
(Supplementary Figure S4e); imipramine (P= 0.007),
CP 156,526 (P= 0.001) and SSR 149415 (P= 0.005),
but not fluoxetine, reversed the changes induced by
CMS. The percentage of mushroom-type spines was
significantly decreased in the distal dendrites of
pyramidal neurons of the PFC in animals exposed to
CMS (F1, 20 = 98.47, P< 0,001); these changes were
normalized by all antidepressants (P< 0.006 in all
cases; Supplementary Figure S4f). In addition,
Figure 3 Three-dimensional morphometric analysis of Golgi-impregnated neurons using computer-assisted reconstructions
of hippocampal and medial prefrontal cortex (PFC) neurons. Representative dentate granule (a), CA3 pyramidal (b) and layer
II/III pyramidal neurons from the prelimbic area of the medial PFC (c) are shown. Cells are depicted in the x-y orthogonal
plan. Total dendritic length of (d) dentate granule neurons in the subgranular zone (SGZ; n= 6 per group; **P< 0.001; #
Pp0.005), (e) CA3 pyramidal neurons (n= 6 per group; **P< 0.001; # Pp0.005) and (f) pyramidal neurons in the PFC (n= 6
per group; **P< 0.001; #Pp0.001). Spine density in the proximal and distal dendrites of (g) dentate granule neurons in the
SGZ, (h) CA3 pyramidal neurons (n= 6 per group; **P< 0.001; #P< 0.011) and (i) pyramidal neurons in the PFC (n= 6 per
group; **P< 0.001; #Pp0.001). Data represented as mean±s.e.m. Asterisk represents the effect of methylazoxymethanol
(MAM) in every experimental group. Double asterisk represents the comparison between control and chronic mild stress
(CMS) groups. Cardinal represents the effect of antidepressant treatment.
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imipramine (P= 0.006), CP 156,526 (P= 0.001) or SSR
149415 (P= 0.001), but not fluoxetine, reversed the
CMS-induced increases in the percentage of thin-type
spines (F1, 20 = 32.57, P< 0.001). Treatment with
MAM, alone or in combination with CMS and/or
antidepressants did not result in any significant
changes in dendritic morphometry in either the
hippocampus or the PFC. No significant changes in
spine morphology were observed in basal dendrites of
pyramidal neurons from the CA3 region of the
hippocampus and the PFC (data not shown).
Gene expression studies
The mRNA expression of Ncam1 and Syn1 was
measured by qPCR. The expression of Ncam1 was
significantly reduced in the hippocampus of CMS rats
(F1, 12 = 73.18, P< 0.001). These changes were reversed
by fluoxetine, imipramine, CP 156,526 and SSR
149415 (P< 0.01 in all cases; Figure 4a). Furthermore,
rats exposed to CMS revealed significantly reduced
levels of Ncam1 expression in the PFC (F1, 12 = 28.73,
P< 0.001) that were reversed by all antidepressants
(P< 0.01 in all cases; Figure 4b). Co-administration
of MAM significantly decreased Ncam1 mRNA levels
in the hippocampus of all experimental groups
(F1, 46 = 8.617, P= 0.005); MAM did not influence
Ncam1 expression in the PFC. Exposure to CMS,
with/without concomitant treatment with MAM
and/or antidepressants, did not alter Syn1 mRNA
expression in the hippocampus (Figure 4c). However,
Syn1 expression was significantly reduced in the PFC
of rats exposed to CMS (F1, 12 = 23.27, P< 0.001) and
reversed by administration of fluoxetine, imipramine,
and SSR 149415, (P< 0.01 in all cases) but not of
CP 156,526 (Figure 4d). With the exception of the
group that had been exposed to CMS, treatment with
MAM led to a significant decrease in Syn1 mRNA
expression in the PFC of all experimental groups
(F1, 46 = 12.809, P= 0.001).
Discussion
The behavioral data obtained confirmed the validity
of CMS as an animal model of depression insofar that
animals exposed to stress exhibited clear signs of
anhedonia (reduced sucrose preference) and learned
helplessness (increased immobility in the FST).
Furthermore, the administration of four antidepres-
sant drugs with different mechanisms of action
significantly attenuated these depressive-like beha-
viors after 1 week (imipramine, CP 156,526 and SSR
149415) or 2 weeks of treatment (fluoxetine). The
analysis of cell proliferation and differentiation in the
hippocampus confirmed previous reports of the
antineurogenic effects of CMS on the one hand,2,9
and the proneurogenic effects of the antidepressant
compounds on the other.8–10 Briefly, the hippocampi
of CMS rats revealed significantly reduced overall
numbers of recently-mitotic (Ki67-positive and BrdU-
positive) cells, a proportion of which were recently-
Figure 4 Antidepressant treatment induced changes in mRNA expression levels of the synaptic remodeling proteins neural
cell adhesion molecule 1 (NCAM1) in (a) the hippocampus (n= 4 per group; **P< 0.001; #P< 0.01) and (b) the prefrontal
cortex (PFC) (n= 4 per group; **P< 0.001; #P< 0.01) and synapsin 1 (SYN1) in (c) the hippocampus and (d) the PFC (n= 4 per
group; **P< 0.001; #P< 0.01). mRNA expressions of Ncam1 and Syn1 were measured by quantitative PCR (qPCR). Data
represented as mean±s.e.m. Asterisk represents the effect of methylazoxymethanol (MAM) in every experimental group.
Double asterisk represents the comparison between control and chronic mild stress (CMS) groups. Cardinal represents the
effect of antidepressant treatment.
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and young neurons (BrdU-positive/NeuN-positive);
CMS did not influence the number of newly born
astroglial cells (BrdU-positive/GFAP-positive). Anti-
depressant treatment not only reversed the antiproli-
ferative effects of CMS, but stimulated neurogenesis
to levels above those found in controls. These
behavioral actions of antidepressants were observed
in animals displaying signs of depressive-like beha-
vior, contrasting with some previous reports that
antidepressants can elicit behavioral effects under
basal conditions.8,10,16 Although temporal coinci-
dence in the occurrence of impaired neurogenesis
and depressive-like symptoms and their reversal by
antidepressant treatment is evident, these data do not
demonstrate a direct cause effect between neurogen-
esis and the alleviation of signs of depressive-like
behavior, and recently it was shown that this action of
antidepressants is mediated indirectly by neurotro-
phins.35 To examine whether antidepressant-induced
neurogenesis may simply be an epiphenomenon, we
tested the therapeutic efficacy of the various anti-
depressants in subsets of rats that were concomitantly
treated with MAM. This cytostatic agent was chosen
because X-ray irradiation17 is likely to induce inflam-
mation and requires a period of recovery before
antidepressants can be administered. Pilot studies
showed that MAM at a dose of 7 mg kg1 per day
reduces neurogenesis, without any undesired effects
on general health. Importantly, the various antide-
pressants ameliorated CMS-induced behavioral signs
of depression to the same extent in vehicle and MAM-
treated animals. These observations indisputably
demonstrate that the mood-improving actions of
antidepressants occur independently of their ability
to stimulate hippocampal neurogenesis.
Signs of anxiety are often present in both depressed
patients and animal models of depression and many
antidepressant drugs have anxiolytic properties.36
Using the NSF paradigm, we found that all anti-
depressant drugs tested significantly reduced the
hyperanxious state observed in CMS-exposed rats.
Importantly, however, ongoing neurogenesis seems
essential for the manifestation of this behavioral effect
of antidepressants. This finding accords with results
from Santarelli et al.17 who, however, interpreted the
results of this behavioral assay as a measure of
antidepressive action. Neurogenesis in the hippocam-
pus was previously shown to be essential for certain
hippocampus-dependent functions, including trace
memory formation27 and spatial learning.37 As the
hippocampus sends major projections to the extended
amygdala, it is plausible that new neurons, generated
in response to antidepressant treatment, integrate into
neuronal networks implicated in emotional behavior
and thereby, modulate anxiety.
Structural changes within the hippocampus and
the PFC are increasingly recognized as key to the
pathophysiology of depression. Although total neu-
ronal numbers in the hippocampus and in the PFC
were not altered by any of the treatments, the CMS
paradigm triggered significant volumetric changes in
both regions. Accordingly, we next analyzed the
potential contribution of synaptic plasticity and
neuronal connectivity to the development of, and
recovery from, depressive-like behavior. By cross-
reference to the behavioral data concerning anhedo-
nia and learned helplessness, it emerges that the
expression of depression-like behavior in CMS rats
tracks dendritic atrophy and loss of synaptic contacts.
Interestingly, even though spine densities were not
altered in any of the experimental groups, we
observed a shift in the ratio between mushroom and
thin spine types, suggesting the possibility of a
change in spine turnover, that is, a subtle but
significant, reflection of altered synaptic function.
Another important finding was that antidepressant
administration to CMS-treated rats concomitantly
reversed signs of depression-like behavior and
restored synaptic connections to a level found in
control animals; these adjustments occurred indepen-
dently of the neurogenic status.
Besides the structural changes within the hippo-
campus and the PFC, the present results support the
view22,24 that some of the behavioral disturbances in
depressed subjects may result from an interruption of
balanced communication between these, and other
brain regions. As compared to controls and antide-
pressant-treated animals, CMS rats showed marked
atrophy of the apical dendrites of neurons in the
hippocampus (dentate gyrus and CA3 areas) and the
PFC (layers II/III, upon which the hippocampal
inputs impinge). The topographic distribution of the
dendritic changes in the PFC observed after CMS and
following antidepressants indicate that interruption
of hippocampus-PFC connectivity may underlie the
manifestation of depressive-like behavior.22,38 Inter-
estingly, the dendritic atrophy and regrowth observed
in this study are consistent with reports in depres-
sed patients of reduced hippocampal and PFC
volumes21,23 as well as their pharmacological reversi-
bility39 (but see reference40). In this context, our
results reinforce the notion that antidepressants may
facilitate rewiring of neural circuits, as demonstrated
recently in amblyopic animals.41
Restoration of synaptic plasticity, reflected in
increased levels of expression of NCAM1,42,43 is
thought to be central to the therapeutic efficacy
antidepressant drugs.1–3 Consistent with this view,
all antidepressant drugs tested in this study rein-
stated hippocampal Ncam1 expression in CMS-
treated animals to levels found in control animals.
Our observation of reduced levels of Ncam1 in the
hippocampus of MAM-treated animals concurs with
the fact that newly born neurons transiently express
Ncam1.44 On the other hand, as postnatal neurogen-
esis does not occur in the PFC, the increased levels of
cell adhesion molecules found in the PFC of anti-
depressant-treated rats (with or without concomitant
dosing with MAM) supports previous suggestions
that synaptic remodeling and plasticity may underlie
the action of antidepressant drugs.45 The observation
Restoration of behavioral homeostasis by antidepressants
JM Bessa et al
771
Molecular Psychiatry
that the expression levels of the gene encoding for the
presynaptic protein SYN1 were only altered in the
PFC, together with our three-dimensional analysis of
dendritic morphology and the results from a previous
study,24 suggest that remodeling of synapses located
on the apical dendrites of pyramidal cells of PFC
layers II/III may be important in the onset and
amelioration of depressive-like behavior.
In summary, the present results demonstrate that
antidepressants, irrespective of their mechanisms of
action, trigger neuronal remodeling and synaptic
plasticity. Moreover, we show that antidepressants
promote hippocampal neurogenesis but that this is
not a critical event for their mood-rectifying actions.
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